赣南医科大学
创新与转化医学研究院
赣南医科大学创新与转化医学研究院是在赣州市人民政府、章贡区人民政府的大力支持下，联合赣南医科大学、国内外知名专家教授共同组建的一所面向国家科技创新战略需求的高端生物医药新型研发机构。
研究院始终围绕习总书记在江西视察时提出的"努力在加快革命老区高质量发展上作示范、在推动中部地区崛起上勇争先"的目标要求，秉持"为科学注入红色基因，用科技服务健康中国"的办院宗旨，坚持面向世界科技前沿、面向经济主战场、面向国家重大需求、面向人民生命健康，聚焦生物医药领域国际前沿，开展临床重大疾病的原创基础和应用研究，引领科技创新，服务当地经济社会发展。
The Ganzhou Innovation and Translational Medicine Research Institute was established with strong support from
the Ganzhou Municipal People’s Government and the Zhanggong District People’s Government,in collaboration with
Gannan Medical University and renowned experts and scholars from China and abroad. It is a high-end, new-type
biopharmaceutical R&D institution oriented toward national science and technology innovation strategies.
Guided by the goals proposed by President Xi Jinping during his inspection of Jiangxi—to set an example in
accelerating high-quality development in former revolutionary base areas and to take the lead in promoting the
rise of central China—the Institute upholds its mission of “infusing science with red genes and serving the
Healthy China initiative through technology.” Adhering to the principles of facing the world’s scientific
frontiers, the main economic battlefield, major national needs, and people’s life and health, the Institute
focuses on cutting-edge biopharmaceutical research, conducts original basic and applied studies on major
clinical diseases, leads scientific innovation, and serves local economic and social development.
目前，研究院拥有一支300余人的生物医学领域科研创新团队，包括院士、国家级高层次人才、省部级人才获得者等50余人，全职落户赣州的“85后”年轻教授30名，招录研究生150余人。未来三年，研究院将源源不断汇聚高层次优秀人才，建设形成一支1500-2000
余人的高科技创新与转化团队。
近年来，研究院已建成创新药物、宠物产业、高端生物试剂三大板块“一站式”全流程研发体系和产业能力，目前，已开发治疗心衰、糖尿病等6个宠物I类新药进入临床，正在研发7个人用I类新药，研发宠物食品100余种，其中26款进入市场。开展研发体外诊断、细胞分析、试剂盒等生物试剂产品3000余种。已孵化科技企业2家。建立宠物大健康研究院、融媒体中心，完成宠物国家标准、宠物指数的发布，推动赣州宠物产业经济集群的快速形成。研究院辐射效应形成，目前，已经吸引了京东京业汇、千麦医疗、昌红科技、美国GHL、华氏医药等一批重要企业入驻赣州，生物医药产业集群效应初显。
未来，研究院将加快实施创新驱动发展战略，开辟创新发展新领域、新赛道，通过汇聚国内外一流高层次人才，加快建设国际一流生物医学科研创新平台，推动科研成果转化和医药大健康产业集群培育壮大，为全面贯彻党的二十大提出的“加快实施创新驱动发展战略、加快实现高水平科技自立自强”作出新的更大贡献！
At present, the Institute has established a biomedical research and innovation team of more than 300 members,
including over 50 academicians, national high-level talents, and provincial- and ministerial-level award
recipients, as well as 30 full-time young professors born after 1985 who have settled in Ganzhou. More than 150
graduate students have been recruited. Over the next three years, the Institute plans to continuously attract
top-tier talents and build a high-tech innovation and translational team of 1,500–2,000 members.
In recent years, the Institute has built a one-stop, full-process R&D and industrial capability system across
three major sectors: innovative pharmaceuticals, the pet industry, and high-end biological reagents. To date,
six Class I innovative pet drugs for indications such as heart failure and diabetes have entered clinical
trials, while seven Class I innovative drugs for human use are under development. More than 100 pet food
products have been developed, with 26 already on the market. In addition, the Institute has developed over 3,000
biological reagent products, including in vitro diagnostics, cell analysis products, and reagent kits, and has
successfully incubated two technology-based enterprises.
The Institute has also established a Pet Health Research Institute and a Media Convergence Center, released
national standards and indices for the pet industry, and actively promoted the rapid formation of a pet industry
economic cluster in Ganzhou. Its growing influence has attracted a number of leading enterprises to settle in
Ganzhou, including JD Jingyehui, Qianmai Medical,Changhong Technology, GHL,and Huashi Pharmaceutical,with an
emerging biopharmaceutical industry cluster now taking shape.
Looking ahead, the Institute will accelerate the implementation of an innovation-driven development strategy,
explore new fields and pathways for innovation, and gather top-tier talents from around the world. By building a
world-class biomedical research and innovation platform, it aims to promote the transformation of scientific
achievements and the growth of the medical and health industry cluster, contributing further to the goals set
forth at the 20th National Congress of the Communist Party of China—namely, accelerating innovation-driven
development and achieving high-level scientific and technological self-reliance.
